Inhibikase Therapeutics, Inc. General form of registration statement for all companies including face-amount certificate companies

Supplemental Balance Sheet Information

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

7. Supplemental Balance Sheet Information

Accrued expenses and other current liabilities consist of the following:


	September 30, 2022		December 31, 2021
Accrued consulting	$	229,661	$	210,000
Accrued compensation		417,573		421,734
Deferred revenue		23,683		—
Accrued research and development		1,586,138		2,077,932
Accrued interest		—		968
Accrued other		32,671		5,127

Total accrued expenses and other current liabilities	$	2,289,726	$	2,715,761

3. Supplemental Balance Sheet Information

Accrued expenses and other current liabilities consist of the following:


	December 31, 2021		December 31, 2020
Accrued consulting	$	210,000	$	115,405
Accrued compensation		421,734		—
Accrued legal and professional fees		—		383,286
Accrued research and development		2,077,932		83,491
Accrued interest		968		1,673
Accrued other		5,127		49,079

Total accrued expenses and other current liabilities	$	2,715,761	$	632,934